Vaxcyte, Inc.: insider trades · United States · SEC (Form 4)

About Vaxcyte, Inc.

Vaxcyte, Inc. is a clinical-stage biotechnology and vaccine company listed on the NASDAQ under ticker PCVX in the United States. Headquartered in San Carlos, California, the company was incorporated in 2013 under the name SutroVax and adopted the Vaxcyte name in 2020. For investors, it represents a specialized growth biotech with a science-led platform and no meaningful commercial product revenue yet, but with substantial optionality if its late-stage vaccine programs continue to advance successfully. Vaxcyte’s business is built around its proprietary platform for designing and manufacturing high-fidelity proteins and antigens. The company’s technology originated from cell-free protein synthesis capabilities licensed from Sutro Biopharma and has been further developed internally to support the creation of next-generation vaccines. The strategic focus is on bacterial diseases, especially pneumococcal infections, where the company believes broader serotype coverage and stronger immune responses can create a better product profile than existing vaccines. Its lead asset is VAX-31, a next-generation pneumococcal conjugate vaccine candidate that management describes as the broadest-spectrum PCV in clinical development, with separate programs in adults and infants. VAX-24 has also been an important part of the company’s clinical validation work. In competitive terms, Vaxcyte is trying to challenge established vaccine leaders in a market that is both medically important and commercially attractive. Pneumococcal vaccination is already a well-developed category, dominated by large pharmaceutical companies with approved products and global scale. Vaxcyte’s investment case therefore hinges on differentiation: wider serotype coverage, robust immunogenicity, and a potential best-in-class profile. The company does not yet have a broad commercial footprint; its geographic presence remains primarily U.S.-based, anchored by its California headquarters and an expanding domestic manufacturing strategy. Recent developments have been especially important. In 2025 and 2026, Vaxcyte reported major clinical progress for VAX-31, including the initiation and enrollment of multiple Phase 3 adult trials and continued advancement of the infant program. The company also published positive clinical data in a respected medical journal, helping strengthen the scientific profile of its lead vaccine candidate. On the manufacturing side, Vaxcyte continued to invest in dedicated production capacity in the United States and in long-term manufacturing agreements, signaling that it is preparing for a potential future commercial launch. Overall, Vaxcyte remains a capital-intensive, high-risk, high-upside biotech story whose valuation will be driven primarily by clinical success, regulatory milestones, and manufacturing execution on the NASDAQ in the United States.